Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Clinical trial NCT05358249 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05358249
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

KRAS G12C Mutant Solid Tumors Carcinoma, Non-Small Cell Lung Carcinoma, Non-Small-Cell Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Carcinoma Nonsmall Cell Lung Cancer Colorectal Cancer Colorectal Carcinoma Colorectal Neoplasms Colorectal Tumors Neoplasms, Colorectal

Start date: 2022-10-24
Primary completion: 2026-09-30
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.